Developing and Using Therapeutics for Emerging Infections
Identifieur interne : 000151 ( Istex/Corpus ); précédent : 000150; suivant : 000152Developing and Using Therapeutics for Emerging Infections
Auteurs : Jeannine S. Mccune ; Kellie S. ReynoldsSource :
- Clinical Pharmacology & Therapeutics [ 0009-9236 ] ; 2015-10.
Abstract
This issue of Clinical Pharmacology & Therapeutics focuses on emerging infections. The outbreaks of the vaccine‐preventable diseases (e.g., measles) and the emerging pathogens (e.g., Ebola) show us how small the world has become. These outbreaks also show the pressing need for effective public education and development of novel therapies. This issue covers various aspects of relevant therapeutic topics ranging from preclinical models, pharmacokinetics, pharmacodynamics, pharmacogenomics, and clinical trial results, to education efforts in this area. Pharmacokinetic/dynamic modeling had an appreciable role in reducing the morbidity and mortality associated with human immunodeficiency virus and hepatitis C virus, recent emerging infections. However, these gains could be lessened by poor adherence to therapies, which has contributed to the development of multidrug‐resistant tuberculosis. We must not forget lessons from previous infections, or they may reemerge.
Url:
DOI: 10.1002/cpt.183
Links to Exploration step
ISTEX:06DBCF2DBEFEBB9445EA2CD450FEC12E9BE024E4Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Developing and Using Therapeutics for Emerging Infections</title><author><name sortKey="Mccune, Jeannine S" sort="Mccune, Jeannine S" uniqKey="Mccune J" first="Jeannine S." last="Mccune">Jeannine S. Mccune</name><affiliation><mods:affiliation>Department of Pharmacy, University of Washington, Washington, USA, Seattle</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: jmccune@u.washington.edu</mods:affiliation></affiliation></author><author><name sortKey="Reynolds, Kellie S" sort="Reynolds, Kellie S" uniqKey="Reynolds K" first="Kellie S." last="Reynolds">Kellie S. Reynolds</name><affiliation><mods:affiliation>Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Maryland, Silver Spring, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:06DBCF2DBEFEBB9445EA2CD450FEC12E9BE024E4</idno><date when="2015" year="2015">2015</date><idno type="doi">10.1002/cpt.183</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-ZJS4G057-8/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000151</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000151</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Developing and Using Therapeutics for Emerging Infections</title><author><name sortKey="Mccune, Jeannine S" sort="Mccune, Jeannine S" uniqKey="Mccune J" first="Jeannine S." last="Mccune">Jeannine S. Mccune</name><affiliation><mods:affiliation>Department of Pharmacy, University of Washington, Washington, USA, Seattle</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: jmccune@u.washington.edu</mods:affiliation></affiliation></author><author><name sortKey="Reynolds, Kellie S" sort="Reynolds, Kellie S" uniqKey="Reynolds K" first="Kellie S." last="Reynolds">Kellie S. Reynolds</name><affiliation><mods:affiliation>Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Maryland, Silver Spring, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Clinical Pharmacology & Therapeutics</title><title level="j" type="alt">CLINICAL PHARMACOLOGY AND THERAPEUTICS</title><idno type="ISSN">0009-9236</idno><idno type="eISSN">1532-6535</idno><imprint><biblScope unit="vol">98</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="346">346</biblScope><biblScope unit="page" to="351">351</biblScope><biblScope unit="page-count">6</biblScope><date type="published" when="2015-10">2015-10</date></imprint><idno type="ISSN">0009-9236</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0009-9236</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">This issue of Clinical Pharmacology & Therapeutics focuses on emerging infections. The outbreaks of the vaccine‐preventable diseases (e.g., measles) and the emerging pathogens (e.g., Ebola) show us how small the world has become. These outbreaks also show the pressing need for effective public education and development of novel therapies. This issue covers various aspects of relevant therapeutic topics ranging from preclinical models, pharmacokinetics, pharmacodynamics, pharmacogenomics, and clinical trial results, to education efforts in this area. Pharmacokinetic/dynamic modeling had an appreciable role in reducing the morbidity and mortality associated with human immunodeficiency virus and hepatitis C virus, recent emerging infections. However, these gains could be lessened by poor adherence to therapies, which has contributed to the development of multidrug‐resistant tuberculosis. We must not forget lessons from previous infections, or they may reemerge.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Jeannine S. McCune</name><affiliations><json:string>Department of Pharmacy, University of Washington, Washington, USA, Seattle</json:string><json:string>E-mail: jmccune@u.washington.edu</json:string></affiliations></json:item><json:item><name>Kellie S. Reynolds</name><affiliations><json:string>Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Maryland, Silver Spring, USA</json:string></affiliations></json:item></author><articleId><json:string>CPT183</json:string></articleId><arkIstex>ark:/67375/WNG-ZJS4G057-8</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>editorial</json:string></originalGenre><abstract>This issue of Clinical Pharmacology & Therapeutics focuses on emerging infections. The outbreaks of the vaccine‐preventable diseases (e.g., measles) and the emerging pathogens (e.g., Ebola) show us how small the world has become. These outbreaks also show the pressing need for effective public education and development of novel therapies. This issue covers various aspects of relevant therapeutic topics ranging from preclinical models, pharmacokinetics, pharmacodynamics, pharmacogenomics, and clinical trial results, to education efforts in this area. Pharmacokinetic/dynamic modeling had an appreciable role in reducing the morbidity and mortality associated with human immunodeficiency virus and hepatitis C virus, recent emerging infections. However, these gains could be lessened by poor adherence to therapies, which has contributed to the development of multidrug‐resistant tuberculosis. We must not forget lessons from previous infections, or they may reemerge.</abstract><qualityIndicators><score>6.099</score><pdfWordCount>2527</pdfWordCount><pdfCharCount>17642</pdfCharCount><pdfVersion>1.5</pdfVersion><pdfPageCount>6</pdfPageCount><pdfPageSize>612 x 800.957 pts</pdfPageSize><pdfWordsPerPage>421</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>131</abstractWordCount><abstractCharCount>972</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Developing and Using Therapeutics for Emerging Infections</title><genre><json:string>editorial</json:string></genre><host><title>Clinical Pharmacology & Therapeutics</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1532-6535</json:string></doi><issn><json:string>0009-9236</json:string></issn><eissn><json:string>1532-6535</json:string></eissn><publisherId><json:string>CPT</json:string></publisherId><volume>98</volume><issue>4</issue><pages><first>346</first><last>351</last><total>6</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Editorial</value></json:item><json:item><value>Editorial</value></json:item></subject></host><ark><json:string>ark:/67375/WNG-ZJS4G057-8</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - pharmacology & pharmacy</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - pharmacology & pharmacy</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Pharmacology (medical)</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Pharmacology, Toxicology and Pharmaceutics</json:string><json:string>3 - Pharmacology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2015</publicationDate><copyrightDate>2015</copyrightDate><doi><json:string>10.1002/cpt.183</json:string></doi><id>06DBCF2DBEFEBB9445EA2CD450FEC12E9BE024E4</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-ZJS4G057-8/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-ZJS4G057-8/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-ZJS4G057-8/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Developing and Using Therapeutics for Emerging Infections</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher ref="https://scientific-publisher.data.istex.fr/ark:/67375/H02-QW5Q88H5-V">Wiley Publishing Ltd</publisher><availability><licence>© 2015 ASCPT</licence></availability><date type="published" when="2015-10"></date></publicationStmt><notesStmt><note type="content-type" subtype="editorial" source="editorial" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-STW636XV-K">editorial</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="editorial"><analytic><title level="a" type="main">Developing and Using Therapeutics for Emerging Infections</title><author xml:id="author-0000" role="corresp"><persName><forename type="first">Jeannine S.</forename><surname>McCune</surname></persName><affiliation><orgName type="division">Department of Pharmacy</orgName><orgName type="institution">University of Washington</orgName><address><settlement>Seattle</settlement><region>Washington, USA</region></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">Kellie S.</forename><surname>Reynolds</surname></persName><affiliation><orgName type="division">Office of Clinical Pharmacology, Office of Translational Sciences</orgName><orgName type="institution">Center for Drug Evaluation and Research, Food and Drug Administration</orgName><address><settlement>Silver Spring</settlement><region>Maryland</region><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><idno type="istex">06DBCF2DBEFEBB9445EA2CD450FEC12E9BE024E4</idno><idno type="ark">ark:/67375/WNG-ZJS4G057-8</idno><idno type="DOI">10.1002/cpt.183</idno><idno type="unit">CPT183</idno><idno type="toTypesetVersion">file:CPT.CPT183.pdf</idno></analytic><monogr><title level="j" type="main">Clinical Pharmacology & Therapeutics</title><title level="j" type="alt">CLINICAL PHARMACOLOGY AND THERAPEUTICS</title><idno type="pISSN">0009-9236</idno><idno type="eISSN">1532-6535</idno><idno type="book-DOI">10.1002/(ISSN)1532-6535</idno><idno type="book-part-DOI">10.1002/cpt.v98.4</idno><idno type="product">CPT</idno><imprint><biblScope unit="vol">98</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="346">346</biblScope><biblScope unit="page" to="351">351</biblScope><biblScope unit="page-count">6</biblScope><date type="published" when="2015-10"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract style="main"><p><hi rend="bold">This issue of <hi rend="italic">Clinical Pharmacology & Therapeutics</hi> focuses on emerging infections. The outbreaks of the vaccine‐preventable diseases (e.g., measles) and the emerging pathogens (e.g., Ebola) show us how small the world has become. These outbreaks also show the pressing need for effective public education and development of novel therapies. This issue covers various aspects of relevant therapeutic topics ranging from preclinical models, pharmacokinetics, pharmacodynamics, pharmacogenomics, and clinical trial results, to education efforts in this area. Pharmacokinetic/dynamic modeling had an appreciable role in reducing the morbidity and mortality associated with human immunodeficiency virus and hepatitis C virus, recent emerging infections. However, these gains could be lessened by poor adherence to therapies, which has contributed to the development of multidrug‐resistant tuberculosis. We must not forget lessons from previous infections, or they may reemerge</hi>.</p></abstract><textClass><keywords rend="articleCategory"><term>Editorial</term></keywords><keywords rend="tocHeading1"><term>Editorial</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-ZJS4G057-8/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en" xml:id="cpt183"><header><publicationMeta level="product"><doi origin="wiley" registered="yes">10.1002/(ISSN)1532-6535</doi><issn type="print">0009-9236</issn><issn type="electronic">1532-6535</issn><idGroup><id type="product" value="CPT"></id></idGroup><titleGroup><title type="main" sort="CLINICAL PHARMACOLOGY AND THERAPEUTICS">Clinical Pharmacology & Therapeutics</title><title type="short">Clin. Pharmacol. Ther.</title></titleGroup></publicationMeta><publicationMeta level="part" position="40"><doi>10.1002/cpt.v98.4</doi><titleGroup><title type="main">Emerging Infections</title></titleGroup><copyright ownership="thirdParty">© 2015 American Society for Clinical Pharmacology and Therapeutics</copyright><numberingGroup><numbering type="journalVolume" number="98">98</numbering><numbering type="journalIssue">4</numbering></numberingGroup><coverDate startDate="2015-10">October 2015</coverDate></publicationMeta><publicationMeta level="unit" position="20" type="editorial" status="forIssue"><doi>10.1002/cpt.183</doi><idGroup><id type="unit" value="CPT183"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="articleCategory">Editorial</title><title type="tocHeading1">Editorial</title></titleGroup><copyright ownership="thirdParty">© 2015 ASCPT</copyright><eventGroup><event type="manuscriptReceived" date="2015-07-08"></event><event type="manuscriptAccepted" date="2015-07-08"></event><event type="xmlCreated" agent="Cenveo Publisher Services" date="2015-07-13"></event><event type="publishedOnlineAccepted" date="2015-07-14"></event><event type="firstOnline" date="2015-09-15"></event><event type="publishedOnlineFinalForm" date="2015-09-15"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.7.5 mode:FullText" date="2016-01-23"></event></eventGroup><numberingGroup><numbering type="pageFirst">346</numbering><numbering type="pageLast">351</numbering></numberingGroup><correspondenceTo>Correspondence: JS McCune (<email>jmccune@u.washington.edu</email>)</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:CPT.CPT183.pdf"></link></linkGroup></publicationMeta><contentMeta><titleGroup><title type="main">Developing and Using Therapeutics for Emerging Infections</title></titleGroup><creators><creator creatorRole="author" xml:id="cpt183-cr-0001" affiliationRef="#cpt183-aff-0001" corresponding="yes"><personName><givenNames>Jeannine S.</givenNames><familyName>McCune</familyName></personName></creator><creator creatorRole="author" xml:id="cpt183-cr-0002" affiliationRef="#cpt183-aff-0002"><personName><givenNames>Kellie S.</givenNames><familyName>Reynolds</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="cpt183-aff-0001" countryCode="US" type="organization"><orgDiv>Department of Pharmacy</orgDiv><orgName>University of Washington</orgName><address><city>Seattle</city><countryPart>Washington, USA</countryPart></address></affiliation><affiliation xml:id="cpt183-aff-0002" countryCode="US" type="organization"><orgDiv>Office of Clinical Pharmacology, Office of Translational Sciences</orgDiv><orgName>Center for Drug Evaluation and Research, Food and Drug Administration</orgName><address><city>Silver Spring</city><countryPart>Maryland</countryPart><country>USA</country></address></affiliation></affiliationGroup><abstractGroup><abstract type="main"><p><b>This issue of <i>Clinical Pharmacology & Therapeutics</i> focuses on emerging infections. The outbreaks of the vaccine‐preventable diseases (e.g., measles) and the emerging pathogens (e.g., Ebola) show us how small the world has become. These outbreaks also show the pressing need for effective public education and development of novel therapies. This issue covers various aspects of relevant therapeutic topics ranging from preclinical models, pharmacokinetics, pharmacodynamics, pharmacogenomics, and clinical trial results, to education efforts in this area. Pharmacokinetic/dynamic modeling had an appreciable role in reducing the morbidity and mortality associated with human immunodeficiency virus and hepatitis C virus, recent emerging infections. However, these gains could be lessened by poor adherence to therapies, which has contributed to the development of multidrug‐resistant tuberculosis. We must not forget lessons from previous infections, or they may reemerge</b>.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Developing and Using Therapeutics for Emerging Infections</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Developing and Using Therapeutics for Emerging Infections</title></titleInfo><name type="personal"><namePart type="given">Jeannine S.</namePart><namePart type="family">McCune</namePart><affiliation>Department of Pharmacy, University of Washington, Washington, USA, Seattle</affiliation><affiliation>E-mail: jmccune@u.washington.edu</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kellie S.</namePart><namePart type="family">Reynolds</namePart><affiliation>Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Maryland, Silver Spring, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="editorial" displayLabel="editorial" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-STW636XV-K">editorial</genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><dateIssued encoding="w3cdtf">2015-10</dateIssued><dateCreated encoding="w3cdtf">2015-07-13</dateCreated><dateCaptured encoding="w3cdtf">2015-07-08</dateCaptured><dateValid encoding="w3cdtf">2015-07-08</dateValid><copyrightDate encoding="w3cdtf">2015</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><abstract>This issue of Clinical Pharmacology & Therapeutics focuses on emerging infections. The outbreaks of the vaccine‐preventable diseases (e.g., measles) and the emerging pathogens (e.g., Ebola) show us how small the world has become. These outbreaks also show the pressing need for effective public education and development of novel therapies. This issue covers various aspects of relevant therapeutic topics ranging from preclinical models, pharmacokinetics, pharmacodynamics, pharmacogenomics, and clinical trial results, to education efforts in this area. Pharmacokinetic/dynamic modeling had an appreciable role in reducing the morbidity and mortality associated with human immunodeficiency virus and hepatitis C virus, recent emerging infections. However, these gains could be lessened by poor adherence to therapies, which has contributed to the development of multidrug‐resistant tuberculosis. We must not forget lessons from previous infections, or they may reemerge.</abstract><relatedItem type="host"><titleInfo><title>Clinical Pharmacology & Therapeutics</title></titleInfo><titleInfo type="abbreviated"><title>Clin. Pharmacol. Ther.</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><genre>article-category</genre><topic>Editorial</topic><topic>Editorial</topic></subject><identifier type="ISSN">0009-9236</identifier><identifier type="eISSN">1532-6535</identifier><identifier type="DOI">10.1002/(ISSN)1532-6535</identifier><identifier type="PublisherID">CPT</identifier><part><date>2015</date><detail type="title"><title>Emerging Infections</title></detail><detail type="volume"><caption>vol.</caption><number>98</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>346</start><end>351</end><total>6</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0001"><titleInfo><title>Platforms for antibiotic discovery</title></titleInfo><name type="personal"><namePart type="given">K.</namePart><namePart type="family">Lewis</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lewis, K. Platforms for antibiotic discovery. Nat. Rev. Drug Discov. 12, 371–387 (2013).</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>371</start><end>387</end></extent></part><relatedItem type="host"><titleInfo><title>Nat. Rev. Drug Discov.</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>371</start><end>387</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0002"><titleInfo><title>Clinical Pharmacology & Therapeutics: The next five years</title></titleInfo><name type="personal"><namePart type="given">S.A.</namePart><namePart type="family">Waldman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Terzic</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Waldman, S.A. & Terzic, A. Clinical Pharmacology & Therapeutics: The next five years. Clin. Pharmacol. Ther. 97, 2–6 (2015).</note><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>97</number></detail><extent unit="pages"><start>2</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>Clin. Pharmacol. Ther.</title></titleInfo><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>97</number></detail><extent unit="pages"><start>2</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0003"><titleInfo><title>Modeling infectious disease dynamics in the complex landscape of global health</title></titleInfo><name type="personal"><namePart type="given">H.</namePart><namePart type="family">Heesterbeek</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Heesterbeek, H. et al. Modeling infectious disease dynamics in the complex landscape of global health. Science 347, aaa4339 (2015).</note><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>347</number></detail><extent unit="pages"><start>aaa4339</start></extent></part><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>347</number></detail><extent unit="pages"><start>aaa4339</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0004"><titleInfo><title>Is measles next?</title></titleInfo><name type="personal"><namePart type="given">L.</namePart><namePart type="family">Roberts</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Roberts, L. Is measles next? Science 348, 958–961 (2015).</note><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>958</start><end>961</end></extent></part><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>958</start><end>961</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0005"><titleInfo><title>Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST‐246 to protect against smallpox in humans</title></titleInfo><name type="personal"><namePart type="given">J.M.</namePart><namePart type="family">Leeds</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Leeds, J.M. et al. Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST‐246 to protect against smallpox in humans. Antimicrob. Agents Chemother. 57, 1136–1143 (2013).</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>57</number></detail><extent unit="pages"><start>1136</start><end>1143</end></extent></part><relatedItem type="host"><titleInfo><title>Antimicrob. Agents Chemother.</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>57</number></detail><extent unit="pages"><start>1136</start><end>1143</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0006"><titleInfo><title>The development of a fully‐integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models</title></titleInfo><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Palsson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Palsson, S. et al. The development of a fully‐integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models. BMC Syst. Biol. 7, 95 (2013).</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>95</start></extent></part><relatedItem type="host"><titleInfo><title>BMC Syst. Biol.</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>7</number></detail><extent unit="pages"><start>95</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0007"><titleInfo><title>The animal rule: the role of clinical pharmacology in determining an effective dose in humans</title></titleInfo><name type="personal"><namePart type="given">K.L.</namePart><namePart type="family">Bergman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bergman, K.L. The animal rule: the role of clinical pharmacology in determining an effective dose in humans. Clin. Pharmacol. Ther. 98, 365–368 (2015).</note><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>365</start><end>368</end></extent></part><relatedItem type="host"><titleInfo><title>Clin. Pharmacol. Ther.</title></titleInfo><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>365</start><end>368</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0008"><titleInfo><title>Guidance for Industry; Product Development Under the Animal Rule (draft)</title></titleInfo><name type="corporate"><namePart>US Food and Drug Administration</namePart></name><name type="corporate"><namePart>HHS</namePart></name><genre>other</genre><part><date>2015</date></part></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0009"><titleInfo><title>World Health Organization (WHO). Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. (World Health Organization (WHO) Geneva, Switzerland, 2014).</title></titleInfo><name type="corporate"><namePart>World Health Organization (WHO)</namePart></name><note type="citation/reference">World Health Organization (WHO). Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. (World Health Organization (WHO) Geneva, Switzerland, 2014).</note><genre>book</genre><originInfo><publisher>World Health Organization (WHO)</publisher><place><placeTerm type="text">Geneva, Switzerland</placeTerm></place></originInfo><part><date>2014</date></part></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0010"><titleInfo><title>Pharmacokinetic and pharmacodynamic comparison of once daily efavirenz (400 mg versus 600 mg) in treatment‐naive HIV‐infected patients: results of the ENCORE1 study</title></titleInfo><name type="personal"><namePart type="given">L.</namePart><namePart type="family">Dickinson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dickinson, L. et al. Pharmacokinetic and pharmacodynamic comparison of once daily efavirenz (400 mg versus 600 mg) in treatment‐naive HIV‐infected patients: results of the ENCORE1 study. Clin. Pharmacol. Ther. 98, 406–416 (2015).</note><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>406</start><end>416</end></extent></part><relatedItem type="host"><titleInfo><title>Clin. Pharmacol. Ther.</title></titleInfo><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>406</start><end>416</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0011"><titleInfo><title>Patient adherence to prescribed antimicrobial drug dosing regimens</title></titleInfo><name type="personal"><namePart type="given">B.</namePart><namePart type="family">Vrijens</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Urquhart</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Vrijens, B. & Urquhart, J. Patient adherence to prescribed antimicrobial drug dosing regimens. J. Antimicrob. Chemother. 55, 616–627 (2005).</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>55</number></detail><extent unit="pages"><start>616</start><end>627</end></extent></part><relatedItem type="host"><titleInfo><title>J. Antimicrob. Chemother.</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>55</number></detail><extent unit="pages"><start>616</start><end>627</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0012"><titleInfo><title>Determinants of virological failure and antiretroviral drug resistance in Mozambique</title></titleInfo><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Ruperez</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ruperez, M. et al. Determinants of virological failure and antiretroviral drug resistance in Mozambique. J. Antimicrob. Chemother. (2015); e‐pub ahead of print.</note><part><date>2015</date></part><relatedItem type="host"><titleInfo><title>J. Antimicrob. Chemother.</title></titleInfo><part><date>2015</date></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0013"><titleInfo><title>Targeting the GI tract to develop novel therapies for HIV</title></titleInfo><name type="personal"><namePart type="given">K.R.</namePart><namePart type="family">Reeves</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Burgener</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N.R.</namePart><namePart type="family">Klatt</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Reeves, K.R., Burgener, A. & Klatt, N.R. Targeting the GI tract to develop novel therapies for HIV. Clin. Pharmacol. Ther. 98, 381–386 (2015).</note><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>381</start><end>386</end></extent></part><relatedItem type="host"><titleInfo><title>Clin. Pharmacol. Ther.</title></titleInfo><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>381</start><end>386</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0014"><titleInfo><title>The ongoing debate of who to treat for chronic hepatitis C virus</title></titleInfo><name type="personal"><namePart type="given">M.G.</namePart><namePart type="family">Ghany</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ghany, M.G. The ongoing debate of who to treat for chronic hepatitis C virus. JAMA Intern. Med. 175, 169–170 (2015).</note><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>175</number></detail><extent unit="pages"><start>169</start><end>170</end></extent></part><relatedItem type="host"><titleInfo><title>JAMA Intern. Med.</title></titleInfo><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>175</number></detail><extent unit="pages"><start>169</start><end>170</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0015"><titleInfo><title>Direct-acting antiviral drug for the treatment of chronic hepatitis c virus infection: interferon free is now</title></titleInfo><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Florian</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Florian, J. et al. Direct-acting antiviral drug for the treatment of chronic hepatitis c virus infection: interferon free is now. Clin. Pharmacol. Ther. 98, 394–402 (2015).</note><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>394</start><end>402</end></extent></part><relatedItem type="host"><titleInfo><title>Clin. Pharmacol. Ther.</title></titleInfo><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>394</start><end>402</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0016"><titleInfo><title>Infectious disease. Combating emerging viral threats</title></titleInfo><name type="personal"><namePart type="given">E.</namePart><namePart type="family">Bekerman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Einav</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bekerman, E. & Einav, S. Infectious disease. Combating emerging viral threats. Science 348, 282–283 (2015).</note><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>282</start><end>283</end></extent></part><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>282</start><end>283</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0017"><titleInfo><title>Cost to Develop and Win Marketing Approval for a New Drug Is $2.6 Billion</title></titleInfo><genre>other</genre><part><date>2014</date></part></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0018"><titleInfo><title>Basic obstetric pharmacology</title></titleInfo><name type="personal"><namePart type="given">Y.</namePart><namePart type="family">Zhao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.F.</namePart><namePart type="family">Hebert</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Venkataramanan</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zhao, Y., Hebert, M.F. & Venkataramanan, R. Basic obstetric pharmacology. Semin. Perinatol. 38, 475–486 (2014).</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>38</number></detail><extent unit="pages"><start>475</start><end>486</end></extent></part><relatedItem type="host"><titleInfo><title>Semin. Perinatol.</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>38</number></detail><extent unit="pages"><start>475</start><end>486</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0019"><titleInfo><title>Optimizing the treatment of H1N1 influenza in pregnancy</title></titleInfo><name type="personal"><namePart type="given">R.H.</namePart><namePart type="family">Beigi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V.C.</namePart><namePart type="family">Pillai</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.</namePart><namePart type="family">Venkataramanan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.N.</namePart><namePart type="family">Caritis</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Beigi, R.H., Pillai, V.C., Venkataramanan, R. & Caritis, S.N. Optimizing the treatment of H1N1 influenza in pregnancy. Clin. Pharmacol. Ther. (this issue) 2015.</note><part><date>2015</date></part><relatedItem type="host"><titleInfo><title>Clin. Pharmacol. Ther.</title></titleInfo><part><date>2015</date></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0020"><titleInfo><title>Directly observed therapy for treating tuberculosis</title></titleInfo><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Karumbi</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Garner</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Karumbi, J. & Garner, P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst. Rev. 5, CD003343 (2015).</note><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>CD003343</start></extent></part><relatedItem type="host"><titleInfo><title>Cochrane Database Syst. Rev.</title></titleInfo><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>CD003343</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0021"><titleInfo><title>Optimizing the clinical pharmacology of tuberculosis medications</title></titleInfo><name type="personal"><namePart type="given">E.F.</namePart><namePart type="family">Egelund</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Alsultan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.A.</namePart><namePart type="family">Peloquina</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Egelund, E.F., Alsultan, A. & Peloquina, C.A. Optimizing the clinical pharmacology of tuberculosis medications. Clin. Pharmacol. Ther. 98, 387–393 (2015).</note><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>387</start><end>393</end></extent></part><relatedItem type="host"><titleInfo><title>Clin. Pharmacol. Ther.</title></titleInfo><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>387</start><end>393</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0022"><titleInfo><title>To address emerging infections, we must invest in enduring systems: the kinetics and dynamics of health systems strengthening</title></titleInfo><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Pastakia</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.</namePart><namePart type="family">Njugana</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P.V.</namePart><namePart type="family">Le</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M.K.</namePart><namePart type="family">Singh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T.P.</namePart><namePart type="family">Brock</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pastakia, S., Njugana, B., Le, P.V., Singh, M.K. & Brock, T.P. To address emerging infections, we must invest in enduring systems: the kinetics and dynamics of health systems strengthening. Clin. Pharmacol. Ther. 98, 362–364 (2015).</note><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>362</start><end>364</end></extent></part><relatedItem type="host"><titleInfo><title>Clin. Pharmacol. Ther.</title></titleInfo><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>362</start><end>364</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0023"><titleInfo><title>Addressing fear, fighting complacency</title></titleInfo><name type="personal"><namePart type="given">S.A.</namePart><namePart type="family">Pergam</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Pergam, S.A. Addressing fear, fighting complacency. Clin. Pharmacol. Ther. 98, 359–361 (2015).</note><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>359</start><end>361</end></extent></part><relatedItem type="host"><titleInfo><title>Clin. Pharmacol. Ther.</title></titleInfo><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>98</number></detail><extent unit="pages"><start>359</start><end>361</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0024"><titleInfo><title>Measles, mandates, and making vaccination the default option</title></titleInfo><name type="personal"><namePart type="given">D.J.</namePart><namePart type="family">Opel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.B.</namePart><namePart type="family">Omer</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Opel, D.J. & Omer, S.B. Measles, mandates, and making vaccination the default option. JAMA Pediatr. 169, 303–304 (2015).</note><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>169</number></detail><extent unit="pages"><start>303</start><end>304</end></extent></part><relatedItem type="host"><titleInfo><title>JAMA Pediatr.</title></titleInfo><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>169</number></detail><extent unit="pages"><start>303</start><end>304</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cpt183-cit-0025"><titleInfo><title>Vaccines. Long‐term measles‐induced immunomodulation increases overall childhood infectious disease mortality</title></titleInfo><name type="personal"><namePart type="given">M.J.</namePart><namePart type="family">Mina</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.J.</namePart><namePart type="family">Metcalf</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R.L.</namePart><namePart type="family">de Swart</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.D.</namePart><namePart type="family">Osterhaus</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B.T.</namePart><namePart type="family">Grenfell</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mina, M.J., Metcalf, C.J., de Swart, R.L., Osterhaus, A.D. & Grenfell, B.T. Vaccines. Long‐term measles‐induced immunomodulation increases overall childhood infectious disease mortality. Science 348, 694–699 (2015).</note><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>694</start><end>699</end></extent></part><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>2015</date><detail type="volume"><caption>vol.</caption><number>348</number></detail><extent unit="pages"><start>694</start><end>699</end></extent></part></relatedItem></relatedItem><identifier type="istex">06DBCF2DBEFEBB9445EA2CD450FEC12E9BE024E4</identifier><identifier type="ark">ark:/67375/WNG-ZJS4G057-8</identifier><identifier type="DOI">10.1002/cpt.183</identifier><identifier type="ArticleID">CPT183</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2015 American Society for Clinical Pharmacology and Therapeutics© 2015 ASCPT</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-14</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-ZJS4G057-8/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000151 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000151 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:06DBCF2DBEFEBB9445EA2CD450FEC12E9BE024E4
|texte= Developing and Using Therapeutics for Emerging Infections
}}
| This area was generated with Dilib version V0.6.33. |  |